Stuttgart - Delayed Quote EUR

Nucana PLC (ADRs) (N04.SG)

0.0970

-0.0280

(-22.40%)

At close: June 13 at 9:56:08 PM GMT+2

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026 Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025 Anticipated Cash Runway Extended into Q4 2026 to Support Key Value-Driving Milestones and Complete the Expansion Study of NUC-7738 EDINBURGH, United Kingdom,

GlobeNewswire 13 days ago

NCNA
NuCana Prices $7 Million Registered Direct Offering

EDINBURGH, United Kingdom, May 06, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company that focuses on significantly improving treatment outcomes for patients with cancer, announced that it has priced a registered direct offering consisting of 10,845,985 American Depository Shares, or ADSs, (or pre-funded warrants in lieu thereof) with each ADS (or pre-funded warrant) accompanied by (i) a Series A warrant to purchase one (1) ADS at an initial exercise p

GlobeNewswire last month

NCNA
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?

Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.

Zacks last month

PFE

ANIP

NCNA
NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738 Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Anticipated Cash Runway Extended into Q3 2025 EDINBURGH, United Kingdom, March 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial r

GlobeNewswire 2 months ago

NCNA
NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress 2024 Announced Promising Phase 1b/2 Data on NUC-3373 in Combination with Pembrolizumab or Docetaxel Anticipated Cash Runway into Q2 2025 EDINBURGH, United Kingdom, Nov. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2024 and provided an update on its clinical development program

GlobeNewswire 6 months ago

NCNA
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Pembrolizumab One Patient Achieved a 100% Reduction in their Target Lesion Patients with Lung Cancer who had Exhausted All Other Treatment Options Achieved Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Docetaxel EDINBURGH, United Kingdo

GlobeNewswire 6 months ago

NCNA
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738’s composition of matter. This patent (US12,054,510) is expected to serve as a key component of the intellectual property protection for NUC-7738, which currently consists of over 80 issued patents worldwide. NUC-7738 is a novel anti-cancer agent currently in a Phase 2 clinical study in combination

GlobeNewswire 8 months ago

NCNA
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

Zacks 8 months ago

NCNA
NuCana's Encouraging Data From Resistant Melanoma Treatment Provides Some Relief After Disappointing Colorectal Cancer Data, Stock Surges

On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) for metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. In this 12-patient cohort, most patients had received at least two prior lines of PD-1 inhibitor therapy. Nine out of twelve (75%) achieved disease control, including two patients who achieved Partial Resp

Benzinga 8 months ago

NCNA
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety ProfileBARCELONA, Spain, Sept. 14, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy. In t

GlobeNewswire 8 months ago

NCNA
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 9 months ago

NCNA
NuCana Stock Plunges On Colorectal Combo Therapy Trial Setback, Ends Mid-Stage Study After Disappointing Data

Thursday, NuCana plc (NASDAQ:NCNA) announced that the NuTide:323 study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee. While there were prognostic imbalances favoring the control arm, the Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan, and bevacizumab (NUFIRI+bev) was unlikely to achieve the study’s primary objective of superior Progression-Free Survival compared to the contr

Benzinga 9 months ago

NCNA
NuCana discontinues Phase II NuTide:323 colorectal cancer study

NuCana called the cancellation of the study, which followed a committee recommendation, a ‘disappointing’ and ‘unexpected outcome’.

Clinical Trials Arena 9 months ago

NCNA

GLDAF
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee NuTide:701 and NuTide:303 Studies Continue Unchanged with Encouraging Data on NUC-7738 plus Pembrolizumab to be Presented at the ESMO Annual Conference in September EDINBURGH, United Kingdom, Aug. 29, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the NuTide:323 study is being discontinued following a pre-planned initial analysis and recommendation from the

GlobeNewswire 9 months ago

NCNA
We're A Little Worried About NuCana's (NASDAQ:NCNA) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 9 months ago

NCNA
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

Key Data Readouts on Track for All Programs in 2024 Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the second quarter ended June 30, 2024 and provided an update on its broad clinical development program with its transformative ProTide therapeutics. As of June 30, 2024, NuCana had cash and cash equivalents of £11.6 million compared to £12.9 million as of March 31, 2024 and £17.2 million at

GlobeNewswire 9 months ago

NCNA

Performance Overview

Return	N04.SG	MSCI WORLD (^990100-USD-STRD)
YTD	-92.60%	+5.21%
1-Year	-96.49%	--
3-Year	-99.37%	+56.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nucana PLC (ADRs) (N04.SG)

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

NuCana Prices $7 Million Registered Direct Offering

Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NuCana's Encouraging Data From Resistant Melanoma Treatment Provides Some Relief After Disappointing Colorectal Cancer Data, Stock Surges

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Top Midday Decliners

NuCana Stock Plunges On Colorectal Combo Therapy Trial Setback, Ends Mid-Stage Study After Disappointing Data

NuCana discontinues Phase II NuTide:323 colorectal cancer study

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

We're A Little Worried About NuCana's (NASDAQ:NCNA) Cash Burn Rate

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

Performance Overview